Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.

PloS one - 1 Jan 2013

Wu Xinqi, Marmarelis Melina E, Hodi F Stephen

Abstract excerpt

Heat shock protein 90 (HSP90) is involved in the regulation of diverse biological processes such as cell signaling, proliferation and survival, and has been recently recognized as a potential target for cancer therapy. Ganetespib is a potent ATP competitive inhibitor of HSP90. Ganetespib downregulated the expression of multiple signal transducing molecules including EGFR, IGF-1R, c-Met, Akt, B-RAF and C-RAF,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to Extracellular Signal-Regulated MAP Kinases
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Inhibitory Concentration 50

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, IGF Type 1

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 23418523
DOI: 10.1371/journal.pone.0056134
PMCID: PMC3572008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.PMID 23418523Read ↗

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.Semantic proximity Read ↗

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.Semantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.Semantic proximity Read ↗

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protractionSemantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Semantic proximity Read ↗

Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.Semantic proximity Read ↗

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.Semantic proximity Read ↗

HSP90 and the cancer transcriptome: a comprehensive review of inhibitors and mechanistic insightsSemantic proximity Read ↗

Heat Shock Protein 90 Inhibition in Imatinib-Resistant Gastrointestinal Stromal TumorSemantic proximity Read ↗

Inhibition of Hsp90: A Multitarget Approach to RadiosensitizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.